This new fund will strengthen the balance sheet of AMILI, following the previous Series A round in June 2022 and will be tackled to penetrate the Indonesian market.
Heaptalk, Jakarta — AMILI, the precision gut microbiome startup based in Singapore, has secured new funding from East Ventures. This injection amplifies its balance sheet, following the earlier fund in a Series A round in June 2022.
This health-tech startup will allocate its newest injection to broaden AMILI business operations into the Indonesian market, focusing on resolving prevalent gut health issues through scientific approaches adjusted to the Indonesian context.
Responding to the new fund, the Co-Founder and Chief Executive Officer of AMILI, Jeremy Lim, his party is honored to partner with East Ventures in enabling doctors and other health professionals to benefit the patients through microbiome science, Beyond medicine; the Founder observes microbiome is critical in food and agritech. Thus, this health technology startup looks forward to contributing to innovations in this field, specifically health-enhancing foods and addressing stunting and malnutrition.
Recent scientific developments and discoveries have made the gut microbiome increasingly recognized as the following frontier for human health. The gut microbiome consists of trillions of bacteria, viruses, and fungi in the digestive tract. Microbiome medicine plays a crucial role in almost every aspect of human health, including digestion, immune function, mental health, and disease prevention. According to this startup, many emerging applications of the gut microbiome unlock new possibilities for personalized medicine and transformative approaches to healthcare.
The primary health services of AMILI
Founded in 2019, this startup conducts advanced gut microbiome sequencing services to assist health professionals in enhancing patient care and probiotic formulations designed for Asia consumers. The company also houses Southeast Asia’s only microbiome transplant bank and has supported transplants across the region.
The company has three core assets that allow it to create and capture value, including a multi-ethnic Asia microbiome database, a microbiome bank with samples stored for metagenomic and metabolomic analysis, and AMILI PRIME, a set of proprietary analytical tools, informatics pipelines, and discovery engines. These assets collectively empower the company to drive advancements in gut health research and deliver innovative solutions to the field.
In its business sail, AMILI has developed multiple microbiome-led applications since its establishment. Through its extensive cooperation with regional research partners, this startup has amassed the world’s largest multi-ethnic microbiome database that enables the development of offerings, such as Singapore’s first at-home gut microbiome testing service and the region’s first probiotic blend that includes prebiotics and postbiotics. Last year, the company co-developed a sustainable prebiotic powder by upcycling unused kale stalks.
“We are glad to welcome the AMILI team to the East Ventures family and excited to support them in advancing precision medicine and personalized health and nutrition by harnessing the potential of the gut microbiome. By conducting a local study and comprehending a gut microbiome in Asia deeply, we will discover new insights and elevate the health intervention adjusted to the existing requisites and people’s welfare in the region,” East Ventures‘s Co-Founder and Managing Partner, Willson Cuaca, said.
